JP2008500009A - 全身性エリテマトーデスの治療のための組成物と方法 - Google Patents

全身性エリテマトーデスの治療のための組成物と方法 Download PDF

Info

Publication number
JP2008500009A
JP2008500009A JP2006532309A JP2006532309A JP2008500009A JP 2008500009 A JP2008500009 A JP 2008500009A JP 2006532309 A JP2006532309 A JP 2006532309A JP 2006532309 A JP2006532309 A JP 2006532309A JP 2008500009 A JP2008500009 A JP 2008500009A
Authority
JP
Japan
Prior art keywords
polypeptide
pro
antibody
acid sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500009A5 (enExample
Inventor
アレクサンダー アッバス，
サラ ボーダリー，
ヒラリー クラーク，
ジル ショーンフェルド，
ピー．， ミッキー ウィリアムズ，
ウィリアム， アイ． ウッド，
トーマス， ディ． ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2008500009A publication Critical patent/JP2008500009A/ja
Publication of JP2008500009A5 publication Critical patent/JP2008500009A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
JP2006532309A 2003-03-03 2004-03-02 全身性エリテマトーデスの治療のための組成物と方法 Pending JP2008500009A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45188403P 2003-03-03 2003-03-03
PCT/US2004/006460 WO2005051988A2 (en) 2003-03-03 2004-03-02 Compositions and methods for the treatment of systemic lupus erythematosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010089887A Division JP2010207229A (ja) 2003-03-03 2010-04-08 全身性エリテマトーデスの治療のための組成物と方法

Publications (2)

Publication Number Publication Date
JP2008500009A true JP2008500009A (ja) 2008-01-10
JP2008500009A5 JP2008500009A5 (enExample) 2009-05-14

Family

ID=34632721

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006532309A Pending JP2008500009A (ja) 2003-03-03 2004-03-02 全身性エリテマトーデスの治療のための組成物と方法
JP2010089887A Pending JP2010207229A (ja) 2003-03-03 2010-04-08 全身性エリテマトーデスの治療のための組成物と方法
JP2013121971A Pending JP2013240329A (ja) 2003-03-03 2013-06-10 全身性エリテマトーデスの治療のための組成物と方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010089887A Pending JP2010207229A (ja) 2003-03-03 2010-04-08 全身性エリテマトーデスの治療のための組成物と方法
JP2013121971A Pending JP2013240329A (ja) 2003-03-03 2013-06-10 全身性エリテマトーデスの治療のための組成物と方法

Country Status (6)

Country Link
US (2) US7749695B2 (enExample)
EP (1) EP1599498A2 (enExample)
JP (3) JP2008500009A (enExample)
AU (2) AU2004293369A1 (enExample)
CA (1) CA2518101A1 (enExample)
WO (1) WO2005051988A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790861B2 (en) * 1999-09-24 2010-09-07 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US7754435B2 (en) * 2000-09-21 2010-07-13 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
WO2007043103A1 (ja) * 2005-09-30 2007-04-19 Kansai Technology Licensing Organization Co., Ltd. シェーグレン症候群診断法及び診断キット
CN101473045B (zh) 2006-04-24 2016-08-03 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物
EP2369016A1 (en) * 2006-05-25 2011-09-28 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for diagnosing and treating graft rejection and inflammatory conditions
EP1905841A1 (en) * 2006-09-25 2008-04-02 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Trex1 as a marker for lupus erythematosus
US20110281750A1 (en) * 2008-07-24 2011-11-17 The Regents Of The University Of California, A California Corporation Identifying High Risk Clinically Isolated Syndrome Patients
US20120251546A1 (en) * 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
CA2812057A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
ES2949865T3 (es) 2012-03-28 2023-10-03 Gadeta B V Intercambio combinatorio de cadena de receptores de células T gamma 9 delta 2
HUE068936T2 (hu) * 2016-06-10 2025-02-28 Gadeta B V Új eljárás tumorellenes vagy fertõzés elleni választ közvetítõ deltaT-sejt- (vagy gammaT-sejt-) receptor-láncok vagy azok részeinek azonosítására
AU2017360043A1 (en) * 2016-11-18 2019-06-20 Hospital Clinic De Barcelona Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
BR112019016374A2 (pt) 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
JP2021510157A (ja) * 2018-01-09 2021-04-15 イマジン ファーマ、エルエルシー 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用
GB202012804D0 (en) * 2020-08-17 2020-09-30 Univ London Queen Mary Agrin polypeptide and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2002543764A (ja) * 1999-03-19 2002-12-24 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４６個のヒト分泌タンパク質
WO2003016475A2 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
JP2005535290A (ja) * 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
JP2006513700A (ja) * 2002-09-25 2006-04-27 ジェネンテック・インコーポレーテッド 乾癬の治療のための新規組成物と方法
JP2006515748A (ja) * 2002-11-12 2006-06-08 ジェネンテック・インコーポレーテッド リウマチ様関節炎の治療のための組成物と方法
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1666192A (en) * 1991-03-22 1992-10-21 Sloan-Kettering Institute For Cancer Research Methods for detection and treatment of cancer
WO2001040465A2 (en) * 1999-11-30 2001-06-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU6498499A (en) * 1998-09-17 2000-04-03 Genentech Inc. Compositions and methods for the treatment of immune related diseases
CA2362427A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2506665T3 (es) * 1999-12-23 2014-10-13 Genentech, Inc. Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos
JP2003529774A (ja) 2000-03-31 2003-10-07 ジェネンテック・インコーポレーテッド 遺伝子発現を検出し定量するための構成物及び方法
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001090304A2 (en) * 2000-05-19 2001-11-29 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001294943A1 (en) * 2000-10-02 2002-04-15 Bayer Corporation Nucleic acid sequences differentially expressed in cancer tissue
US20020137081A1 (en) * 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
CA2435260A1 (en) 2001-01-19 2002-07-25 Incyte Genomics, Inc. Receptors and membrane-associated proteins
WO2003010327A2 (en) * 2001-02-21 2003-02-06 Curagen Corporation Novel proteins and nucleic acids encoding same
US6489153B1 (en) * 2001-10-31 2002-12-03 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US7118865B2 (en) * 2002-08-16 2006-10-10 Regents Of The University Of Minnesota Methods for diagnosing severe systemic lupus erythematosus
EP1578373A4 (en) * 2002-09-11 2007-10-24 Genentech Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
WO2004047728A2 (en) * 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543764A (ja) * 1999-03-19 2002-12-24 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４６個のヒト分泌タンパク質
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2003016475A2 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
JP2005535290A (ja) * 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
JP2006513700A (ja) * 2002-09-25 2006-04-27 ジェネンテック・インコーポレーテッド 乾癬の治療のための新規組成物と方法
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
JP2006515748A (ja) * 2002-11-12 2006-06-08 ジェネンテック・インコーポレーテッド リウマチ様関節炎の治療のための組成物と方法

Also Published As

Publication number Publication date
JP2013240329A (ja) 2013-12-05
AU2011202082A1 (en) 2011-05-26
JP2010207229A (ja) 2010-09-24
WO2005051988A3 (en) 2005-07-28
US20110142841A1 (en) 2011-06-16
CA2518101A1 (en) 2005-06-09
US7749695B2 (en) 2010-07-06
AU2004293369A1 (en) 2005-06-09
US20090054300A1 (en) 2009-02-26
WO2005051988A2 (en) 2005-06-09
EP1599498A2 (en) 2005-11-30
AU2004293369A2 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
JP5401001B2 (ja) 免疫関連疾患の治療のための新規組成物と方法
JP4901747B2 (ja) 免疫関連疾患の治療のための新規組成物と方法
EP2444409A2 (en) Compositions and methods for the treatment of immune related diseases
JP2012254093A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2006516094A (ja) ナチュラルキラー細胞関連疾患の治療のための組成物と方法
JP2006515747A (ja) 免疫関連疾患の治療のための組成物と方法
JP2010207229A (ja) 全身性エリテマトーデスの治療のための組成物と方法
JP2010162016A (ja) 乾癬の治療のための新規組成物と方法
JP2005535290A (ja) 免疫関連疾患の治療のための組成物と方法
JP2010088434A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2006515167A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2011177176A (ja) 乾癬の治療のための新規組成物と方法
JP2013051961A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2006521810A (ja) 免疫関連疾患の治療のための新規組成物と方法
JP2005519590A (ja) 免疫関連疾患の治療のための組成物及び方法
JP2013048621A (ja) 免疫関連疾患の治療のための組成物と方法
JP2006515748A (ja) リウマチ様関節炎の治療のための組成物と方法
JP2006519582A (ja) 乾癬の治療のための新規組成物と方法
US20070248588A1 (en) Novel Compositions and Methods for the Treatment of Immune-Related Diseases
EP1923400A1 (en) Compositions and methods for the treatment of systemic lupus erythematosis
HK1118838A (en) Compositions and methods for the treatment of systemic lupus erythematosis
HK1163696A (en) Method to determine b cell mediated diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100308

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111101